SeQuent Scientific Ltd (SEQUENT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:SeQuent Scientific Ltd (SEQUENT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3312
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
SeQuent Scientific Ltd (SeQuent) is a pharmaceutical company that develops and manufactures animal health API, life science and industrial products. The company offers products such as aciclovir sodium, albendazole, artemether, artesunate, amyl meta cresol, citicoline sodium and dihydroartemisinin. SeQuent provides analytical solutions such as method validation, stability, microbiology. The company’s products are used in the therapeutic areas of anti-malarial, anthelmintics, anti-infective, antiviral, CNS and dermatology. It serves API, pharmaceutical, personal care, institutional and nutraceutical companies. The company operates through its veterinary API manufacturing, animal health formulation, GLP compliant facilities in India and Turkey. SeQuent is headquartered in Mumbai, Maharashtra, India.

SeQuent Scientific Ltd (SEQUENT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
SeQuent Scientific Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
SeQuent Scientific Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
SeQuent Scientific Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
SeQuent Scientific Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
SeQuent Scientific Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
SeQuent Scientific Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Shasun Pharma To Sell Active Pharmaceutical Ingredients Manufacturing Facility 10
Licensing Agreements 11
Gilead Sciences Expands Licensing Agreement with SeQuent Scientific 11
Equity Offering 12
SeQuent Scientific Limited Raises USD62.8 Million in Private Placement of Shares 12
SeQuent Scientific Raises USD8.36 Million in Private Placement of Shares 13
Acquisition 14
SeQuent Scientific to Acquire Remaining Stake in Alivira Animal Health for USD12 Million 14
SeQuent Scientific To Acquire Arvee Syntthesis 15
Sequent Scientific To Acquire Minority Stake In Shasun Pharma For Us$27 Million 16
SeQuent Scientific Ltd – Key Competitors 17
SeQuent Scientific Ltd – Key Employees 18
SeQuent Scientific Ltd – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Joint Venture 19
Recent Developments 20
Financial Announcements 20
Aug 09, 2018: SeQuent Scientific announces Q1 FY19 financial results 20
May 24, 2018: SeQuent Scientific Announces Q4 & FY18 Financial Results 21
Feb 09, 2018: SeQuent Scientific Announces Q3 FY1 8 Financial Results 22
Nov 09, 2017: Sequent Scientific Announces Q2 FY 18 Financial Results 24
Aug 03, 2017: SeQuent Scientific Announces Q1 FY1 8 Financial Results 26
May 23, 2017: SeQuent Scientific Announces FY17 Financial Results 27
Feb 10, 2017: SeQuent Scientific announces Q3FY17 Financial Results 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
SeQuent Scientific Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
SeQuent Scientific Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
SeQuent Scientific Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
SeQuent Scientific Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
SeQuent Scientific Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
SeQuent Scientific Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Shasun Pharma To Sell Active Pharmaceutical Ingredients Manufacturing Facility 10
Gilead Sciences Expands Licensing Agreement with SeQuent Scientific 11
SeQuent Scientific Limited Raises USD62.8 Million in Private Placement of Shares 12
SeQuent Scientific Raises USD8.36 Million in Private Placement of Shares 13
SeQuent Scientific to Acquire Remaining Stake in Alivira Animal Health for USD12 Million 14
SeQuent Scientific To Acquire Arvee Syntthesis 15
Sequent Scientific To Acquire Minority Stake In Shasun Pharma For Us$27 Million 16
SeQuent Scientific Ltd, Key Competitors 17
SeQuent Scientific Ltd, Key Employees 18
SeQuent Scientific Ltd, Subsidiaries 19
SeQuent Scientific Ltd, Joint Venture 19

List of Figures
SeQuent Scientific Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
SeQuent Scientific Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
SeQuent Scientific Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
SeQuent Scientific Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
SeQuent Scientific Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
SeQuent Scientific Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
SeQuent Scientific Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
SeQuent Scientific Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[SeQuent Scientific Ltd (SEQUENT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nymox Pharmaceutical Corp (NYMX):医療機器:M&Aディール及び事業提携情報
    Summary Nymox Pharmaceutical Corp (Nymox) is a biopharmaceutical company that undertakes the research and development of therapeutics and diagnostics devices to target the unmet needs of the aging population. The company markets diagnostic products for measuring tobacco product exposure and for the …
  • Vitro, S.A.B. de C.V.:企業の戦略・SWOT・財務情報
    Vitro, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report Summary Vitro, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Daniel Thwaites Plc:企業の戦略・SWOT・財務情報
    Daniel Thwaites Plc - Strategy, SWOT and Corporate Finance Report Summary Daniel Thwaites Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • iiNet Limited:企業の戦略・SWOT・財務情報
    iiNet Limited - Strategy, SWOT and Corporate Finance Report Summary iiNet Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Nucor Corporation:戦略・SWOT・企業財務分析
    Nucor Corporation - Strategy, SWOT and Corporate Finance Report Summary Nucor Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Avantium NV (AVTX):企業の財務・戦略的SWOT分析
    Avantium NV (AVTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • MedImmune LLC-製薬・医療分野:企業M&A・提携分析
    Summary MedImmune LLC (MedImmune), a subsidiary of AstraZeneca Plc, is a biotechnology company. It focuses on the research, development, manufacture and marketing of small molecules and biologics to address some of the major medical needs. The company develops therapeutic proteins, monoclonal antibo …
  • Kang Stem Biotech Co Ltd (217730):製薬・医療:M&Aディール及び事業提携情報
    Summary Kang Stem Biotech Co Ltd (Kang Stem Biotech) is a biopharmaceutical company that develops stem cell therapeutic products for the treatment of incurable diseases using umbilical cord blood-derived stem cells. The company’s stem cell therapy products include Furestem-AD for treating subacute a …
  • KKR & Co. L.P.:企業の戦略・SWOT・財務情報
    KKR & Co. L.P. - Strategy, SWOT and Corporate Finance Report Summary KKR & Co. L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Equinor ASA.:企業の戦略・SWOT・財務分析
    Equinor ASA. - Strategy, SWOT and Corporate Finance Report Summary Equinor ASA. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Takara Bio Inc (4974):企業の財務・戦略的SWOT分析
    Summary Takara Bio Inc (Takara) a subsidiary of Takara Holdings Inc, is a biotechnology company engaged in the production and distribution of research reagents and scientific instruments. The company is involved in providing quality research products to life science researchers across the world. It …
  • Lee Enterprises, Inc. (LEE):企業の財務・戦略的SWOT分析
    Lee Enterprises, Inc. (LEE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Precipio Inc (TBIO):企業の財務・戦略的SWOT分析
    Summary Precipio Inc (Precipio), formerly known as Transgenomic Inc, develops diagnostic tools. The company advances personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. Precipio uses ICE COLD-P …
  • TAXIS Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary TAXIS Pharmaceuticals Inc (TAXIS Pharma) is a healthcare products company that offers drug discovery services. The company develops and discovers pharmaceuticals targeting infectious diseases. It identifies new classes of antibiotic agents use a novel mechanism of bactericidal action differe …
  • Crescendo Bioscience Inc-医療機器分野:企業M&A・提携分析
    Summary Crescendo Bioscience Inc (Crescendo), a subsidiary of Myriad Genetics Inc is a molecular diagnostics company that concentrates on rheumatology. The company develops quantitative, objective, and biology based tests for rheumatologists. Its vectra DA is an advanced blood test for rheumatoid ar …
  • OSE Immunotherapeutics (OSE):企業の財務・戦略的SWOT分析
    Summary OSE Immunotherapeutics (OSE), formerly OSE Pharma SA is a biotechnology company that discovers and develops immunotherapy products against invasive and metastatic late-stage cancers. The company’s memopi technology is employed in studying the development of treatments for ovarian, colon and …
  • UCO Bank:企業の戦略・SWOT・財務情報
    UCO Bank - Strategy, SWOT and Corporate Finance Report Summary UCO Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Navios Maritime Partners L.P.:企業のM&A・事業提携・投資動向
    Navios Maritime Partners L.P. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Navios Maritime Partners L.P. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • SARomics Biostructures AB:製薬・医療:M&Aディール及び事業提携情報
    Summary SARomics Biostructures AB (Saromics) is a contract research organization that offers structural biology and drug discovery outsourcing services platform for biotech and pharmaceutical companies. The organization provides services in protein crystallization, protein crystallography, protein N …
  • Tullow Oil plc:戦略・SWOT・企業財務分析
    Tullow Oil plc - Strategy, SWOT and Corporate Finance Report Summary Tullow Oil plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆